CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.
This report contains market size and forecasts of Chemotherapy Induced Peripheral Neuropathy Treatment in global, including the following market information:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Chemotherapy Induced Peripheral Neuropathy Treatment companies in 2021 (%)
The global Chemotherapy Induced Peripheral Neuropathy Treatment market was valued at 1723.6 million in 2021 and is projected to reach US$ 2613.1 million by 2028, at a CAGR of 6.1% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Calcium Channel ?2-delta Ligands Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment include Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc and DermaXon LLC, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Chemotherapy Induced Peripheral Neuropathy Treatment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment Percentages, by Type, 2021 (%)
Calcium Channel ?2-delta Ligands
Antidepressants
Opioids
Others
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment Percentages, by Application, 2021 (%)
Platinum Agents
Taxanes
Vinca Alkaloids
Others
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Chemotherapy Induced Peripheral Neuropathy Treatment revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Chemotherapy Induced Peripheral Neuropathy Treatment revenues share in global market, 2021 (%)
Key companies Chemotherapy Induced Peripheral Neuropathy Treatment sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Chemotherapy Induced Peripheral Neuropathy Treatment sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
Kineta Inc
Krenitsky Pharmaceuticals Inc
PeriphaGen
Apexian Pharma
WinSanTor

LEAVE A REPLY

Please enter your comment!
Please enter your name here